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Chemotherapy for advanced colorectal patients: daily practice results 
may not reflect the outcomes of prospective clinical trials
Krzysztof Adamowicz1, Jacek Jassem2
Introduction. Colorectal cancer is the second cause of cancer deaths worldwide. The development of new drugs in 
recent years has improved the outcomes, but it is not clear whether this progress also includes patients managed 
in daily clinical practice. Treatment outcomes in patients with advanced colorectal cancer treated in Poland outside 
of clinical trials are scare.
Methods. We analyzed the results of first-line chemotherapy in 165 patients with advanced colorectal cancer treated 
between May 2010 and December 2013 in two institutions.
Results. The mean patient age was 61 ± 8.7 years; 105 patients received irinotecan-based regimens (CLF1 or XELIRI), 
41 oxaliplatin-based regimens (FOLFOX4 or XELOX) and 19 patients received single-agent 5-fluorouracil. A partial 
response was achieved in 48 patients (29%), stable disease in 71 (43%) and 46 patients (28%) progressed during 
treatment. Median survival in the entre group was 14 months. Respective average response rate and median overall 
survival in recent clinical trials were 39% and 17 months, respectively. Compared to single agent treatment, multi-
drug chemotherapy was associated with increased general toxicity (p = 0.039), in particular with higher occurrence 
of diarrhea (p = 0.003) and peripheral neuropathy (p < 0.001). There was no apparent impact of chemotherapy on 
overall quality of life. 
Conclusions. Treatment results of advanced colorectal cancer in daily practice may be worse than those obtained in 
prospective clinical trials. The use of palliative chemotherapy has no noticeable impact on quality of life.
NOWOTWORY J Oncol 2016; 66, 4: 285–292
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Introduction
Colorectal cancer is the third most common malignancy 
in the world and the second most common cause of cancer 
mortality, with 1.3 million new cases and 700,000 deaths 
recorded annually [1]. According to the National Cancer 
Registry in Poland, around 16,200 cases of colorectal cancer 
are diagnosed per year [2]. Despite certain progress in early 
diagnosis and therapy during past decades, approximately 
50% of patients still die within 5 years of diagnosis [3]. Pa-
tients with multi-organ metastases who are not candidates 
for surgery have a particularly poor prognosis [4, 5].
Within the past decade the median survival of metastatic 
colorectal cancer patients treated within clinical trials has 
increased from 12 to over 20 months [6, 7]. Such improve-
ments have been achieved by virtue of introduction new 
therapeutic options, such as long-term infusion of 5-fluoro-
uracil (5-FU) with leucovorin (LV) biomodulation instead of 
short term 5-FU infusions [8], or by the use of new cytotoxics, 
such as irinotecan or oxaliplatin [9]. A better understand-
ing of the biology of colorectal cancer has also led to the 
development of molecular targeted drugs including the 
anti-angiogenic monoclonal antibody bevacizumab and the 
anti-EGFR (epidermal growth factor receptor) monoclonal 
antibodies cetuximab and panitumumab.
However, patients selected for prospective clinical trials 
are typically in good general condition, with no significant 
286
comorbidities and with unaffected organ functions. In con-
trast, patients managed routinely are usually older, with worse 
general health and with more comorbidities. Thus, it is impor-
tant to learn whether patient outcomes achieved in clinical 
studies apply to a daily clinical practice. Apart from standard 
treatment outcomes, such as overall survival and disease-free 
survival, an important endpoint for new therapeutic strate-
gies is treatment toxicity and the impact of treatment on 
patient’s quality of life. Whereas toxicity is routinely assessed 
within the context of clinical trials, the quality of life is evalu-
ated less frequently. In Poland, the data on the outcomes of 
palliative chemotherapy in patients with advanced colorectal 
cancer are scare. This study, by assessing the efficacy of pal-
liative chemotherapy in a large group of patients treated in 
daily clinical practice, aims at filling this gap.
Materials and methods
The study group included 165 patients with metastatic 
colorectal cancer (ICD10 C18 to C20), who from May 2010 
to December 2013, received palliative chemotherapy at the 
Specialist Hospital in Wejherowo and the Regional Oncology 
Centre in Gdansk, Poland. Included were patients with a 
primary or secondary spread of cancer, ineligible for resec-
tion of metastatic lesions. Clinical data were obtained from 
source patient documentation. In total, 171 patient records 
were analysed, 6 of which were excluded due to incomplete 
documentation. The individual patient data were coded to 
secure complete anonymity. 
The clinical database contained the following informa-
tion; age, gender, education, cigarette status, alcohol con-
sumption, family history of cancer, height, weight, severity 
of pain, diagnosis according to the ICD-10 classification, and 
the administered treatment. Those currently smoking were 
defined as having smoked at least one cigarette per day 
during the previous 12 months. Ex-smokers were defined 
as those not having smoked for the previous 12 months, 
whilst non-smokers were those who had never compulsively 
smoked. A positive cancer family history was based on the 
anamnesis and was defined as the presence of colorectal 
cancer in relatives of the first and/or second degree. Weight 
and height were measured for all patients at baseline. The 
treatment response was assessed retrospectively using the 
RECIST 1.1 criteria, based on subsequent computed tomog-
raphy (CT), and was performed centrally by an experienced 
radiologist, independently of local assessments.
Treatment toxicity was assessed during the first day of 
planned chemotherapy cycle, irrespective of the schedule, 
using the World Health Organization (WHO) classification for 
adverse drug reactions. Haematological toxicity was based 
on laboratory testing results on the day of chemotherapy. 
Other adverse side effects were analysed from patient medi-
cal records.
The quality of life was assessed using the Polish lan-
guage version of the European Organisation for Research 
and Treatment of Cancer (EORTC) QLQ-C30 questionnaire 
[10]. Patients completed questionnaires within the last week 
prior to starting chemotherapy, and in the first week after 
its completion.
Results were analysed with basic descriptive statistics. 
The Student’s t-test was used to assess the significance of 
differences between two variables, whilst ANOVA was used 
for comparisons including more than two variables. Logistic 
regression was used to assess the relationship between 
the applied treatment regimen and response (stratified 
by age, gender, family history, alcohol consumption and 
cigarette smoking). A p-value below 0.05 was considered 
statistically significant. Additionally, the regression and cor-
relation analyses were performed. Sufficient sample size 
was determined and no external validation was performed.
The association between individual factors and patient 
survival was evaluated using Cox Proportional Hazard Re-
gression together with the Likelihood Ratio Test. Treatment 
toxicity and quality of life for particular treatment regimens 
were evaluated using logistic regression after adjusting 
for age, gender, family history, alcohol consumption and 
cigarette smoking. Statistical calculations were performed 
using Microsoft Excel version 2003 and PQStat programme, 
version 1.4. The study was approved by the directors of both 
participating centres and by the Bioethics Committee at the 
Regional Medical Chamber in Gdansk.
Results
Patient ages ranged between 41 to 84 years (mean 61 ± 
± 8.7 years), 53% of patients were women and 62% pre-
sented with primary metastatic cancer (Table I). Colon and 
rectal cancers included 82% and 18% of patients, respec-
tively. Of the 165 subjects, 98 (59%) had earlier received 
postoperative chemotherapy, including 79 (81%) who were 
administered oxaliplatin.
Irinotecan chemotherapy (CLF1 or XELIRI) was given to 
105 patients, 41 received the FOLFOX4 or XELOX regimen, 
whilst the remaining 19 received single-agent 5-fluorouracil 
(5FU) with leucovorin biomodulation. Treatment regimens 
were unrelated to gender (p = 0.087), place of residence 
(p = 0.21), smoking habit (p = 0.49) and to primary or sec-
ondary tumour dissemination (p = 0.85). Single agent 5FU 
chemotherapy was more often administered to patients 
aged over 70 years (p < 0.001). Likewise, the oral route of 
drug administrating was more frequently used in patients 
aged over 70 years and to those from rural areas (p < 0.001 
and < 0.024 respectively). Single drug chemotherapy was 
more commonly used in patients with poorer performance 
status (p < 0.001). There were no correlations between age 
and the performance status (p = 0.33).
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A partial response was achieved in 48 patients (29%), in 
71 (43%) the tumour was stable and 46 patients (28%) de-
veloped progression. In the parametric multivariate analysis 
treatment response was not associated with performance 
status (p = 0.93), age (p = 0.65), type of chemotherapy 
(p = 0.53), education (p = 0.92), gender (p = 0.37), primary 
versus secondary dissemination (p = 0.96), cigarette smo-
king (p = 0.55) and place of residence (p = 0.38).
Of the 165 subjects, 17 remained alive at the time of the 
analysis. The median survival for the entire group was 14 
months. Multivariate analysis showed that survival was sig-
nificantly affected by the performance status and response 
to treatment. There was also a trend towards a shorter sur-
vival in patients treated with single-agent 5FU and for el-
derly patients (Table II). There was no difference between the 
groups administered oxaliplatin and irinotecan (p = 0.74).
The most common adverse reactions were haematologi-
cal toxicity including neutropenia, thrombocytopenia and 
anaemia, along with peripheral neuropathy, vomiting and 
diarrhoea (Table III); less frequent were infection, alopecia, 
weakness and constipation. Overall toxicity was not associ-
ated with performance status (p = 0.22), gender (p = 0.35), 
education (p = 0.13), place of residence (p = 0.56), family 
history (p = 0,41), cigarette smoking (p = 0.27), primary 
or secondary tumour dissemination (p = 0.85), diabetes 
(p = 0.11), hypertension (p = 0.36) and treatment response 
(p = 0.79). General toxicity, however, depended on the type 
of chemotherapy (single-agent 5FU versus multi-drug regi-
mens; p = 0.039) and age (below versus above 65 years; 
p = 0.006). Specific toxicity differences induced diarrhoea 
(p = 0.003) and peripheral neuropathy (p < 0.001). Overall 
toxicity was not related to the chemotherapy regimen 
(irinotecan versus oxaliplatin; p = 0.88). The occurrence of 
peripheral neuropathy was higher in patients with diabe-
tes (p = 0.039). Diarrhoea was more frequent in patients 
receiving irinotecan-based regimens, whereas peripheral 
neuropathy occurred more often in patients receiving 
oxaliplatin.
The average number of chemotherapy cycles for all 
patients was 6 (range, 2 to 11 cycles) and was not related to 
treatment regimen (p = 0.67). There were no toxicity-related 
deaths, however due to toxicity 306 (15.1%) chemotherapy 
cycles had to be postponed. Serious adverse events (WHO 
grade 3 and 4 WHO) occurred in 89 patients (54%). The 
most common causes for deferrals were neutropenia (73%; 
including 2.3% of febrile neutropenia), diarrhoea (8.5%), 
anaemia (6.5%), thrombocytopenia (4.9%) and neuropathy 
(4.9%). Dose reduction was applied in 9 patients (5.4%), 6 of 
whom had peripheral neuropathy and 3 febrile neutropenia. 
In 3 patients (1.8%) treatment was discontinued due to 
neuropathy. The severity of pain before and after treatment 
did not differ significantly (p = 0.34) and was unrelated to 
treatment response (p = 0.09).
Since the quality of life assessment was introduced in 
January 2013 only 49 patients were assessed; the aver-
age age of those was 61 ± 7.9 years. The quality of life was 
not associated with age, gender, place of residence and 
treatment response. The small size of this group, however, 
precluded a meaningful analysis of the quality of life ac-
cording to chemotherapy regimens. The only two changes 
that occurred during chemotherapy included increase in 
diarrhoea and pain relief (Table IV).
Second-line chemotherapy was administered in 148 pa-
tients (90%) and was abandoned in another 16 due to poor 
Table I. Patient clinical features 
Characteristic Numbers
Performance/fitness status  
0 79 (48%)
1 60 (36%)
2 26 (16%)
Localisation
Rectum 30 (18%)
Colon 135 (82%)
Age (years))
41–50 10 (6%)
51–60 82 (50%)
61–70 46 (28%)
71–84 27 (16%)
Gender
Women 88 (53%)
Men 77 (47%)
Family history of cancer
Yes 15 (9%)
No 150 (91%)
Place of residence
Urban 97 (59%)
Rural 68 (41%)
Smoking cigarettes
Yes 73 (44%)
No 92 (56%)
Education
Below secondary level 48 (29%)
Secondary 72 (44%)
Higher 45 (27%)
Cancer dissemination
Primary 102 (62%)
Secondary 63 (38%)
Chemotherapy regimen
CLF1/XELIRI 105 (64%)
FOLFOX/XELOX 41 (25%)
LF/capecitabine 19 (11%)
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performance status and or patient refusal (Table V). Second-
line chemotherapy was rarely used in patients who had 
received first-line single-agent 5FU. Patients who received 
irinotecan as first-line chemotherapy were subsequently 
administered oxaliplatin with the optional addition of beva-
cizumab, whereas those treated with first-line oxaliplatin 
most frequently received irinotecan in the second-line.
Median survival of patients who received only one 
chemotherapy line was shorter compared with those treat-
ed with subsequent chemotherapy lines (10.5 versus 14.1 
months; p < 0.01). Patients receiving first-line irinotecan and 
oxaliplatin as second-line chemotherapy showed similar sur-
vival times compared to those with the opposite sequence 
(median 13.8 versus 13.6 months, p = 0.31). The median 
survival of patients who additionally received second-line 
bevacizumab was 14.1 months, and did not differ from that 
following exclusive chemotherapy (p = 0.73). The RAS-family 
gene mutation was evaluated in 93 patients (56%), and was 
absent in 45 (48%). Third-line treatment was administered in 
39 patients and included monoclonal anti-EGFR antibodies: 
cetuximab or panitumumab.
Discussion
In this series, the median survival was 14 months and 
response rate was 29%. These outcomes seem to be lower 
compared to those reported in recent prospective clinical tri-
als (average median survival of 16.9 months, mean response 
rate 39%, Table VI). As expected, survival was longer in pa-
tients administered two or more lines of therapy compared 
to those administered only one-line therapy, likely due to 
differences in clinical characteristics between these groups. 
Indeed, the second-line chemotherapy was generally not 
considered in patients with a poor performance status or 
rapid progression. The retrospective nature of this study, 
however, does not allow for assessment of the survival im-
pact of second-line chemotherapy.
Inferior study outcomes compared to those in clinical 
trials should be treated with caution since our assumptions 
were based on comparisons between retrospective series 
of patients. Our series included consecutive groups of pa-
tients from two institutions, with no formal selection such 
as performance status, disease comorbidity or other factors 
typically considered in clinical trials. There were 27 subjects 
aged over 70 years, including 4 that were over 80 years, the 
group with higher occurrence of chronic comorbidities. In 
addition, standard regimens used in this series (irinotecan, 
oxaliplatin, single-agent 5-FU) might have been less effec-
tive than those used in clinical trials. Further, even though 
only 17 patients had censored survival data, the retrospec-
Table II. Overall survival according to demographics and clinical factors 
(multivariate analysis) 
Variable Risk factor (95% Cl) p
ECOG performance status 1.44 (1.11–1.88) 0.006
Chemotherapy regimen 0.72 (0.51–1.02) 0.067
Age 0.97 (0.94–1.00) 0.059
Education 1.07 (0.83–1.38) 0.593
Gender 0.98 (0.67–1.44) 0.933
Place of residence 1.01 (0.68–1.52) 0.94
Treatment centre 1.03 (0.73–1.53) 0.97
Cigarette smoking 0.71 (0.48–1.05) 0.08
Treatment response 0.44 (0.34–0.57) < 0.001
Table III. Treatment toxicity; significant differences marked in bold 
Toxicity Indicator Grade 3 and 4 toxicities
CLF1/XELIRI FOLFOX/XELOX 5FU P
Vomiting Number of episodes/applications (%) 88/1074 (8.2% 29/386 (7.5%) 13/191 (6.8%)
0.072
Average toxicity WHO (95% CI) 0.62 (0.48–0.77) 0.56 (0.44–0.69) 0.59 (0.46–0.72)
Diarrhoea Number of episodes/applications (%) 125/1074 (11.6%) 35/386 (9.1%) 14/191 (7.3%)
0.003
Average toxicity WHO (95% CI) 1.31 (1.13–1.49) 0.60 (0.51–0.71) 0.70 (0.56–0.85)
Number of episodes/applications (%) 48/1074 (4.5) 15/386 (3.7) 9/191 (4.7)
0.94
Average toxicity WHO (95% CI) 0.20 (0.11–0.30) 0.18 (0.11–0.25) 0.20 (0.1–0.31)
Anaemia Number of episodes/applications (%) 76/1074 (7.1%) 25/386 (6.5%) 9/191 (4.7%)
0.12
Average toxicity WHO (95% CI) 0.53 (0.43–0.63) 0.52 (0.43–0.62) 0.5 (0.37–0.63)
Thrombocytopenia Number of episodes/applications (%) 46/1074 (4.3%) 14/386 (3.6%) 5/191 (2.6%)
0.19
Average toxicity WHO (95% CI) 0.44 (0.33–0.54) 0.43 (0.35–0.51) 0.37 (0.26–0.48)
Neutropenia Number of episodes/applications (%) 333/1074 (31%) 112/386 (29%) 50/191 (26%)
0.79
Average toxicity WHO (95% CI) 1.22 (0.99–1.4) 1.22 (1.08–1.36) 1.17 (0.98–1.37)
Peripheral neuropathy Number of episodes/applications (%) 31/1074 (2.9%) 37/386 (9.6%) 0/191 (0%)
< 0.001
Average toxicity WHO (95% CI) 0.23 (0.12–0.31) 0.65 (0.53–0.75) 0
95% CI — confidence interwal 95%
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tive nature of the study did not allow for considering such 
factors as comorbidities or previous surgery. The lower re-
mission rates might have also been due to a relatively long 
interval (average 3.8 weeks) between initial CT evaluation 
and chemotherapy commencement, usually not allowed 
in clinical trials.
Regardless of the different characteristics of patients man-
aged in routine practice and in clinical trials, it is important 
to consider the representativeness of a given patient sample 
in relation to the general population of colorectal cancer 
patients. A large majority of colorectal cancer cases (94%) 
in Poland occur in persons aged over 50 years and in 75% 
of those aged over 60 years; with the men/women ratio of 
1.5–2 [2]. Most of the patients in this series were aged 51–70 
years (mean 61 years) and more than a half were women. This 
structure may reasonably reflect the actual demographics of 
advanced colorectal cancer patients in Poland.
In 1.8% of cases in this series treatment had to be discon-
tinued due to toxicity, whilst 5.5% needed reduced doses of 
chemotherapy. Serious adverse events (WHO grade 3 and 
4) occurred in 89 patients (54%), and 23 patients developed 
at least two serious side effects. Such results do not signifi-
cantly differ from those reported in large clinical trials [6, 
8, 9, 11–15]. Nevertheless, our toxicity data may have been 
underestimated due to several reasons. Firstly, our study 
showed that some symptoms, such as lethargy and fatigue 
were relatively rare, likely due to their omissions in medical 
records. The patient’s mental status was an overall deemed 
satisfactory, without depressed mood or any sleep disorders. 
Information on the adverse side effects were nonetheless 
incomplete because of the retrospective nature of our study, 
resulting in inevitably inferior data collection compared 
with the on-line recording required in clinical trials. This dis-
crepancy, however, did not include analytically measurable 
Table IV. Patient quality of life (EORTC QLQ C-30) before and after treatment; significant differences marked in bold 
Average before treatment  
(standard deviation)
Average after treatment  
(standard deviation
General quality of life/ health status 65 (18.5) 66 (17.4) 0.78
Physical fitness 78 (16.7) 80 (14.9) 0.43
Role 87 (19.9) 87 (18.2) 0.73
Emotional functions 76 (12.6) 78 (10.8) 0.67
Cognitive functions 94 (11.3) 92 (13.3) 0.82
Societal functions 85 (24.9) 85 (22.8) 0.76
Symptoms
Fatigue 21 (22.8) 26 (19.6) 0.08
Nausea / vomiting 5.5 (12.7) 7.0 (11.2) 0.15
Pain 21 (19.4) 17 (18.3) 0.03
Dyspnoea 8.2 (11.2) 10 (12.2) 0.67
Insomnia 36 (29.0) 37 (28.0) 0.89
Appetite loss 9.0 (19.0) 11 (18.3) 0.73
Constipation 7.5 (13.5) 6.3 (14.3) 0.81
Diarrhea 6.5 (8.2) 15 (22.4) < 0.001
Financial problems 38 (28.0) 39 (26.7) 0.62
Table V. Second and third line treatment regimens according to first-line chemotherapy
First-line (N) Second-line (N) Third-line(N)
CLF1/XELIRI FOLFOX4/XELOX Cetuximab/panitumumab
FOLFOX4+ bevacizumab Cetuximab/panitumumab
Not used Not applicable
FOLFOX4/XELOX CLF1/XELIRI Cetuximab/panitumumab
LF3 Not used 
Not used Not applicable
LF3 XELOX Not used 
CLF1 Not used 
Not used Not applicable
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Table VI. Outcomes of palliative treatment for colorectal cancer patients in phase III trials since 1998, excluding trials using targeted therapies (detailed 
data and references available from authors) 
Author Year Primary endpoint Median survival 
(months)
Response rate (RR) Number of 
patients
Kohne 1998 RR 19.6 44% 236
Bandealy 1998 RR 12.0 13% 182
Borner 1998 OS 12.4 22% 309
Glimelius 1998 RR, Toxicity BD 27% 203
Cocconi 1998 RR, OS, TTP 12.3 19% 495
Aranda 1998 RR 12.0 30% 306
Colucci 1999 RR and OS 12.0 24% 204
Hausmaninger 1999 RR, OS and TTP 12.6 36% 249
Giacchetti 2000 RR 19.9 53% 200
Douillard 2000 RR 17.4 49% 387
de Gramont 2000 PFS 16.2 51% 420
Saltz 2000 PFS 14.8 39% 683
Sobrero 2000 RR 14.8 32% 214
Hoff 2001 RR 13.3 25% 605
O’Dwyer 2001 Toxicity 14.8 16% 1120
Van Cutsem 2001 RR 13.2 19% 602
Blanke 2002 TTP 16.8 26% 382
Punt 2002 PFS 13.4 29% 365
Schilsky 2002 OS 14.5 12% 981
Comella 2002 OS 14.8 36% 234
Douillard 2002 OS 13.4 15% 816
Kohne 2003 OS 13.7 17% 497
Tournigand 2004 PFS 21.5 56% 220
Goldberg 2004 TTP 19.5 31% 795
Comella 2005 RR 18.9 44% 274
Colucci 2005 RR 15.0 34% 360
Kohne 2005 PFS 20.1 62% 430
Tournigand 2006 PFS 21.2 59% 620
Hospers 2006 RR 13.8 34% 302
Souglakos 2006 OS 21.5 43% 285
Giacchetti 2006 OS 19.6 42% 564
Falcone 2007 RR 22.6 60% 244
Diaz-Rubio 2007 TTP 20.8 46% 348
Porschen 2007 PFS 18.8 54% 474
Seymour 2007 OS 15.4 BD 2135
Glimelius 2008 PFS 19.0 49% 567
Cassidy 2008 PFS 19.8 48% 2034
Gamelin 2008 RR 22.0 34% 208
Aranda 2008 RR 21.6 57% 346
Cunningham 2008 OS 15.9 54% 725
Chibaudel 2009 PFS 23.8 60% 210
Madi 2012 OS 15.4 BD 2397
Qvortrup 2010 Toxicity 17.6 56% 141
Labianca 2011 OS 18.0 42% 337
Mean 16.9 39%
OS — Overall survival; PFS — Progression free survival; TTP — Time to progression; RR — Response ratio; BD — No data
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parameters, such as peripheral blood cell counts. Indeed, 
proportions of patients with neutropenic fever and grade 3 
and 4 peripheral neuropathy was slightly higher compared 
to the literature data [11–15]. It should also be noted that 
some patients were managed by their general practitioners 
and other physicians and such symptoms might have not 
been captured in the analysed records.
Only 9 patients (5.5%) needed hospitalisation during 
treatment, in all cases due to anaemia requiring blood trans-
fusion. Such results indicate that palliative chemotherapy in 
advanced colorectal cancer patients may usually be carried 
out safely on an outpatient basis. Notably, at both participat-
ing institutions patients treated with irinotecan routinely 
received atropine, and those peripheral neuropathy — a 
symptomatic treatment. Most patients also received second-
ary prophylaxis with granulocyte-colony stimulating factors, 
thereby reducing the risk of neutropenia. The severity of 
neuropathy was higher in patients with diabetes, but this 
relationship should be considered with caution, as only a 
small group of patients had been diagnosed with this co-
morbidity. Similarly to other studies, the toxicity was higher 
in patients administered multidrug regimens, compared to 
single-agent 5FU. The study results seem to indicate that 
chemotherapy toxicity in clinical practice may be actually 
be higher than that recorded in clinical trials.
The chemotherapy used in our study had no apparent 
impact on the overall quality of life, and neither was there 
association between treatment response and the quality of 
life. Indeed, we have previously demonstrated that systemic 
palliative chemotherapy has relatively modest influence on 
the quality of life in patients with advanced malignancies 
[16, 17]. An important symptom affecting quality of life was 
treatment-related diarrhoea. The pain relief observed during 
treatment requires cautious interpretation. Firstly, there was 
generally no connection between pain relief and treatment 
response, and secondly, effective pain management might 
have masked its actual intensity. Our study did not evaluate 
how depression or mood disorders affect general health. 
Earlier studies demonstrated that the quality of life is signifi-
cantly worse in colorectal cancer patients with high levels 
of anxiety and depression [18]. This therefore indicates the 
need for considering the impact of other factors other than 
treatment on quality of life in cancer patients administered 
palliative chemotherapy.
Our study provides data on treatment pattern in meta-
static colorectal cancer patients managed in daily clinical 
practice in Poland. Applied methods generally followed 
current therapeutic guidelines, with individualised decisions 
wherever necessary. Most patients received first-line chemo-
therapy regimens containing newer generation drugs — 
irinotecan (64%) or oxaliplatin (25%). Single-agent 5-FU 
chemotherapy was mostly used in elderly or fragile patients. 
The reason for more frequent use of irinotecan-based regi-
mens was probably mainly due to the previous exposure 
to oxaliplatin as a part of postoperative chemotherapy. 
Another important factor were the regulations for the use of 
bevacizumab in Poland, including its reimbursement only in 
second-line treatment in combination with oxaliplatin. De-
spite this, most patients managed with first-line irinotecan 
did not receive bevacizumab in the second line, likely due its 
limited availability or failure to meet the required inclusion 
criteria. Monoclonal anti-EGFR antibodies are reimbursed 
in Poland for patients undergoing third-line treatment for 
wild-type RAS mutation cancers, and the majority of patients 
meeting this criterion actually received this medication.
Conclusions
The study illustrates the current practice and efficacy of 
palliative chemotherapy in Polish patients with advanced 
colorectal cancer. Our results suggest that the outcomes of 
routine treatment in this population may be inferior than 
those reported in clinical trials, typically including care-
fully selected groups of patients. This conclusion, however, 
should be drawn cautiously due to the retrospective nature 
of our study. Nevertheless, this data indicates the need for 
cautions extrapolation of the results from clinical trials into 
daily clinical practice.
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